| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2026―Apr―28 |
Therapeutic strategies encompassing monoclonal antibodies and vaccines to tackle the SARS-CoV-2 Omicron variant amongst European children |
S. A. Kumar, Fuyong Jiao, S. C. Kumar, Lei Ma |
| 2 |
[GO] |
2026―Apr―28 |
A hypothesis: Bitter taste receptors as a therapeutic target for the clinical symptoms of SARS-CoV-2 |
S.A. Kumar, Weyland Cheng |
| 3 |
[GO] |
2026―Apr―28 |
COVID-19 vaccination clinical trials should consider multiple doses of BCG |
|
| 4 |
[GO] |
2026―Apr―28 |
Analysis of COVID-19 mRNA Vaccine-induced Mouth Ulcers Using the Japanese Adverse Drug Event Report Database |
T. Onoda, H. Tanaka, H. Matsuo, M. Takigawa, M. Satoh, T. Ishii |
| 5 |
[GO] |
2026―Apr―28 |
The role of ACE2 in the renin-angiotensin-system: Etiology and therapy of COVID-19 from a pharmaceutical perspective |
C. R. Noe, M. Noe-Letschnig |
| 6 |
[GO] |
2026―Apr―28 |
Avoiding COVID-19 complications with diabetic patients could be achieved by multi-dose Bacillus Calmette-Guérin vaccine: a case study of beta cells regeneration |
B.M. Ayoub, E. Ramadan, N. Ashoush, M. M. Tadros, M. S. Hendy, M. M. Elmazar, S. A. Mousa |
| 7 |
[GO] |
2026―Apr―28 |
Quantification of ivermectin in veterinary products consumed off-label as a treatment for COVID-19 |
C. Wentzel, N. Gernandt, M. Gerber, F. Van Der Kooy |
| 8 |
[GO] |
2026―Apr―28 |
Recent advances of therapeutic targets and potential drugs of COVID-19 |
W. Zhang, P. Zhang, G. Wang, W. Cheng, J. Chen, X. Zhang |
| 9 |
[GO] |
2026―Apr―28 |
Repurposing and discovery of transmembrane serine protease 2 (TMPRSS2) inhibitors as prophylactic therapies for new coronavirus disease 2019 (COVID-19) |
Hao Yang, Xinxin Lin, Qimeng Yu, Annoor Awadasseid, Wen Zhang |
